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The aims of this investigation were to calculate the pharmacokinetic parameters 
and to identify parameters, based on individual plasma concentration-time curves 
of amoxicillin and clavulanic acid in cats, that may govern the observed 
differences in absorption of both drugs. The evaluation was based on the data 
from plasma concentration-time curves obtained following a single-dose, open, 
randomised, two-way crossover phase-I study, each involving 24 female cats 
treated with two Amoxi-Clav formulations (formulation A was Clavubactin and 
formulation was B Synulox; 80/20 mg, 24 animals, 48 drug administrations). 
Plasma amoxicillin and clavulanic acid concentrations were determined using 
validated bioassay methods. The half-life of elimination of amoxicillin is 1.2 h (t1/2 
= 1.24 ± 0.28 h, Cmax = 12.8 ± 2.12 µg/ml), and that of clavulanic acid 0.6 h (t1/2 = 0.63 
± 0.16 h, Cmax = 4.60 ± 1.68 µg/ml). There is a ninefold variation in the AUCt of 
clavulanic acid for both formulations, while the AUCt of amoxicillin varies by a 
factor of two. The highest clavulanic acid AUCt values indicate the best 
absorption; all other data indicate less absorption. Taking into account that the 
amoxicillin–to–clavulanic acid dose ratio in the two products tested was 4:1, the 
blood concentration ratios may actually vary much more, apparently without 
compromising the products’ high efficacy against susceptible microorganisms. 
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Clavulanic acid broadens the antibacterial spectrum of amoxicillin by rendering β-lactamase–
producing strains susceptible to amoxicillin[1]. The binding of β-lactamases with clavulanic acid 
is a complex physicochemical process. In general, the initially formed complex is rapidly 
depleted as covalent binding leads to the irreversible inactivation of the β-lactamase and 
clavulanic acid. Clavulanic acid has thus been termed a 'suicide' inhibitor for β-lactamases. As a 
result of this inhibition, compounds such as amoxicillin, which would normally have been 
hydrolysed to an extent of 10–20% and bound by β-lactamase, are spared. As both amoxicillin 
and clavulanic acid are both absorbed after oral administration and possess similar 
pharmacokinetic properties, they offer a rational antimicrobial combination[2,3,4,5,6]. 
In humans, the standard dose of amoxicillin/clavulanic acid for adults with lower respiratory 
tract infection has, for many years, been 500/125 mg orally t.i.d. A fixed dosage ratio of 
amoxicillin/clavulanic acid (in humans 4:1 or 7:1), assumes that there is little variation in the 
absorption of the drug from the pharmaceutical formulation and that the plasma concentration 
ratio, and the respective AUC values of both compounds, are more or less constant[3,5]. 
However, in humans, bioequivalence studies with the drug ratios 500/125 and 875/125 mg have 
demonstrated that clavulanic acid shows unpredictable absorption and AUC values, hence 
challenging the principle of the fixed-dose ratio (Vree et al., personal observation).  
The pharmacokinetics of amoxicillin and clavulanic acid in cats are not well known. As both 
drugs are eliminated via renal excretion, it is speculated that the drugs would show similar 
pharmacokinetic properties to those in humans. 
This pharmacokinetic evaluation is a follow-up to a bioequivalence study in which two 
40/10-mg tablets (25/6.25 mg/kg) Clavubactin® formulations administered to cats showed 
bioequivalence despite a ninefold variation in the AUCt values of clavulanic acid[7].  
The aims of this study were to describe the plasma concentration-time curves of amoxicillin 
and clavulanic acid in cats, to calculate pharmacokinetic parameters, and to identify parameters 
that may govern the differences in release and absorption of both drugs. 
MATERIALS AND METHODS 
Animals 
Twenty-four adult female cats (strain Hsd/Cpb: CADS) were obtained from Harlan Winkelman 
(D33178 Borchen, Germany). Three cats were housed in one kennel; the room temperature was 
kept at 19.5 ± 3.5oC and relative humidity was kept between 40 and 80%.The animals received 
cat food 4MM, 0.9 MRAD (Hope Farm, 3440 AB Woerden, the Netherlands). 
Experimental Design 
The evaluation was based on the data from plasma concentration-time curves obtained from a 
single-dose, open, randomised, two-way, crossover phase-I study, each involving 24 female cats 
treated with two Amoxi-Clav formulations (24 cats, 48 drug administrations). Treatments were 
separated by a 3-week washout period. 
The clinical trials were performed by Harlan Bioservice (Walsrode, D-29664 Germany) in 
accordance with the requirements of the guidelines: EEC Council directives 81/852/EEG, 28-09-
1981, and 92/18/EEC 20-03-1992. The study protocols were granted approval by the Institutional 
Animal Ethics committee of Harlan. 




For each study, the animals were divided randomly into two groups. Randomisation was carried 
out by procedure PLAN of the SAS Institute (Cary, NC). Group 1 was assigned to treatment 
sequence I–II (formulation I-II). Group 2 was assigned to sequence II–I. During the two crossover 
sessions, cats received each of the two formulations following an overnight fast: 
• Formulation A = single oral dose of two Clavubactin 40/10-mg tablets (Le Vet BV, 
Oudewater, the Netherlands); 50 mg amoxicillin trihydrate and 12.5 mg potassium salt of 
clavulanic acid; mg based on free base);  
• Formulation B = single oral dose of two Synulox 50 mg, (Pfizer, Capelle aan de IJssel, 
the Netherlands). The Clavubactin tablets were made 20% smaller (40/10 mg) to match 
the Synulox tablets. 
The 24 healthy female domesticated cats without any comedication (body weight 3.14 ± 0.40 kg, 
range 2.50–3.76 kg) received 26.2 ± 3.1 mg/kg of amoxicillin and 6.55 ± 0.77 mg/kg of 
clavulanic acid (target dose of 25/6.25 mg). 
Drugs 
• Amoxicillin: [2S-[2α,5α,6β(S*)]]-6-[[amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-
oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. C16H19N3O5S, MW 365.41, [α]20D = 
+246o, CAS 26787-78-0. Trihydrate, CAS 61336-70-7. 
• Clavulanic acid : (Z)-(2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-Azabicyclo 
[3.2.0]heptane-2carboxylic acid. C8H9NO5, MW 199.16, CAS 58001-44-8. 
Drug Administration 
Before drug administration, the cats fasted for at least 10 h. Fasting was continued until 4 h after 
dosing. On the day of the experiment, food was offered for about 30 min at 4 h after drug 
administration. All other days, food was offered ad libitum at about 09.00 h for about 30 min/day. 
Tap water was continuously available ad libitum via bowls. 
The tablets were administered to the animals on the base of the tongue. Together with the 
tablets, each animal received a small volume of water in order to assure the correct intake. 
One cat was too aggressive and refused to blood sampling, thus leaving 23 cats for 
evaluation. 
Blood Sampling 
Blood samples (3 ml) were withdrawn from the jugular vein using a needle No. 14, 23G × 1.25" 
(0.6 × 30mm). They were collected in heparinised glass tubes just before dosing, and at 0.25, 
0.50, 0.75, 1, 1.3, 1.6, 2, 2.5, 3, 4, 5, 7, and 10 h after dosing. The blood samples were centrifuged 
at 3,500 rpm for 10 min and plasma was separated. 
 




The plasma samples were divided into two analysis samples by transferring them into 
polypropylene tubes. Subsequently the samples were diluted 9+1 with two different phosphate 
buffers: for amoxicillin, the samples were diluted with 1-M potassium phosphate buffer; for 
clavulanic acid the samples were diluted with a 1-M sodium phosphate buffer. The samples were 
stored at –70ºC until analysed. 
Bioanalysis 
Plasma amoxicillin and clavulanic acid concentrations were determined using a validated 
bioassay (FarmaResearch, Nijmegen, the Netherlands). Lower limit of quantitation (LOQ) values 
were 10 ng/ml for both drugs. The average amoxicillin recovery from cat plasma was 92.3 ± 
6.46% and for clavulanic acid 95.8 ± 7.93%. 
For the spiked quality control standards of amoxicillin, the interday precision ranged from 
1.42–0.24% CV (low-high QC samples). The intraday precision was 1.27–1.07% CV (low-high 
QC samples). For the spiked quality control standards of clavulanic acid, the interday precision 
ranged from 1.49–0.44% CV (low-high QC samples). The intraday precision of the clavulanic 
assay ranged from 1.19–0.88% CV (low-high QC samples). There was no interference between 
both drugs on each assay. 
Pharmacokinetics 
Based on the plasma amoxicillin and clavulanic acid concentrations of individual animals, the 
following pharmacokinetic parameters were determined by noncompartmental analysis using 
SAS 6.12 (SAS Institute Inc., 1989): maximum plasma drug concentration (Cmax: µg/ml); time to 
reach Cmax (tmax, h); area under the plasma concentration-time curve up to the last measurable 
concentration (Ct), calculated by the linear trapezoidal method (AUCt, µg.h/ml); AUCt/kg is the 
AUCt corrected for the body weight of the individual animal; elimination half-life associated with 
the terminal slope of a semilogarithmic concentration-time curve (t1/2z, h), calculated as ln2/λz, 
where λ is the elimination rate constant. 
Statistical Analysis 
Analysis of variance (ANOVA) was carried out, and significance was defined at p ≤ 0.05. 
RESULTS 
The mean plasma concentration-time curves of amoxicillin and clavulanic acid in 23 healthy 
female cats after oral administration of two 40/10-mg Clavubactin tablets are shown in Fig. 1a. 
The half-life of elimination of amoxicillin is 1.2 h (t1/2 1.24 ± 0.28 h, Cmax 12.8 ± 2.12 µg/ml), and 
that of clavulanic acid is 0.6 h (t1/2 0.63 ± 0.16 h, Cmax 4.60 ± 1.68 µg/ml). Fig. 1b shows the 
pharmacokinetic profile of Synulox. Some pharmacokinetic parameters for both drugs are 
summarised in Table 1. The two formulations were bioequivalent. 
 
 





FIGURE 1a. Mean plasma concentration-time curves of amoxicillin (squares) and clavulanic acid (dots) after an oral dose of 26/6 
mg/kg Clavubactin to 24 healthy female cats (A formulation). The t1/2 of the mean amoxicillin curve is 1.2 h (1.24 ± 0.28 h, n = 23) 




FIGURE 1b. Mean plasma concentration-time curves of amoxicillin and clavulanic acid after an oral dose of 26/6 mg/kg Synulox 
to 23 healthy female cats (B formulation). The t1/2 of the mean amoxicillin curve is 1.5 h (1.51 ± 0.21 h, n = 23) and that of clavulanic 
acid 0.6 h (0.61 ± 0.16 h, n = 23).  
 
 
Fig. 2 shows a plot of the AUCt amoxicillin vs. the AUCt clavulanic acid after oral administration of two 
40/10-mg Clavubactin® tablets of both formulations. There is a ninefold variation in the AUCt of 
clavulanic acid for both formulations (range 13.3–1.45 µg.h/ml), while the corresponding AUCt 
of amoxicillin varies by a factor of two. The mean ratio of the AUCt amoxicillin/clavulanic acid is 
7.32 ± 3.49 for formulation A and 9.45±5.60 for formulation B (p = 0.13, Table 1). 
 




Some Pharmacokinetic Variables of Amoxicillin (80 mg) and Clavulanic Acid (20 mg) in 
Female Cats (n = 23, Body Weight 3.14 ± 0.40 kg) 
 
 Amoxicillin Clavulanic Acid 
 A B A B 
Dosage mg/kg 26.2 ± 3.07 26.0 ± 3.11 6.55 ± 0.77 6.86 ± 0.81 
Cmax (µg/ml) 12.8 ± 2.12 12.0 ± 3.12 4.60 ± 1.68 3.84 ± 1.82 
tmax (h) 1.47 ± 0.44 1.57 ± 0.43 0.72 ± 0.26 0.81 ± 0.23 
t1/2 (h) 1.24 ± 0.28 1.51 ± 0.21 0.63 ± 0.16 0.61 ± 0.16 
AUCt  µg.h/ml 38.4 ± 4.64 38.1 ± 7.85 6.16 ± 2.19 5.49 ± 2.67 
AUCt/kg 12.4 ± 2.14 12.7 ± 3.65 2.00 ± 0.77 1.73 ± 1.02 
Ratio AUCt 7.32 ± 3.49 9.45 ± 5.60   
p 0.13    
Note: A = formulation A, Clavubactin®; B = formulation B, Synulox®; Ratio AUCt amoxicillin/clavulanic acid 







FIGURE 2. Individual AUCt values of clavulanic acid plotted vs. the corresponding AUCt amoxicillin values in 2 × 23 female cats. 
Solid dots = formulation A, open dots = formulation B. It can be noticed that there is a ninefold variation in the AUCt values of 
clavulanic acid, while the variation for amoxicillin is less (2×). Dotted lines represent the 95% confidence interval.  
 
   
 
Fig. 3 shows a plot of the AUCt amoxicillin vs. the AUCt clavulanic acid after oral administration of 
two 40/10-mg Clavubactin® tablets. The AUCt values are corrected for the body weight of the 
individual cats. The mean AUCt/kg values for amoxicillin are 12.4 ± 2.14 vs. 12.7 ± 3.65 
µg.h/ml/kg for formulations A and B (p = 0.55), respectively, and for clavulanic acid 2.00 ± 0.77 
vs. 1.73 ± 1.02 µg.h/ml/kg (p = 0.53, Table 1). 
 





FIGURE 3. Individual AUCt values of clavulanic acid corrected for the body weight (kg) plotted vs. the corresponding AUCt 
amoxicillin values in 2 × 23 cats. Solid dots = formulation A, open dots = formulation B. It can be noticed that there is a ninefold 













Fig. 4 shows the whole data set of AUCt/kg values of both formulations in 2 × 23 cats (Fig. 
3). Three apparent groups of data can be distinguished, each characterised by a regression line.  
An upper tangent (y = 2.31x + 11.47; r = 0.97), a lower tangent (y = –0.12x + 9.5; r = 0.23), 
and an intermediate group (y = 0.84x + 11.0, r = 0.47) of data can be distinguished.  Both the 
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slopes and the y-intercepts of the three apparent data groups (high-medium-low) are statistically 
different. The statistical differences between the slopes are high-medium, p < 0.0001, high-
medium, p < 0.0001; high-low, p < 0.0001. The statistical differences between the y-intercepts 
are high-medium, p = 0.0308, high-medium, p < 0.0001; high-low, p < 0.0001. 
DISCUSSION 
In the animals, the distribution of the data with the Clavubactin® and Synulox® formulations is 
at random. The clavulanic acid AUCt data range from 0.5–4.5 µg.h/ml/kg, i.e, by a factor of nine. 
This variation in AUCt is not seen when clavulanic acid was administered alone[8,9]. When the 
AUCt values were corrected for the body weight of the cats, the picture in Figs. 3 and 4 shows 
clear apparent upper and lower values in the AUCt values. In humans, with high dosage 
amoxicillin 875 mg (≈10 mg/kg), the Cmax broadens, indicating a rate-limiting step in the 
absorption process[10,11,12,13,14,15]. Figs. 3 and 4 suggest that there are three apparent groups 
or situations demonstrating a saturable absorption of amoxicillin (high y-intercept) due to the 
high dosage of 26 mg/kg. While there is still an increase in the AUCt of clavulanic acid, the AUCt 
of amoxicillin in each of the three apparent groups reaches a plateau value or increases only 
slightly. The t1/2 amoxicillin is twice that of clavulanic acid, which may indicate extended 
absorption due to the high dose (Table 1). Normally the elimination t1/2 of both drugs is 
similar[16,17,18,19]. 
With dogs, a similar behaviour was observed, but initially there was a clear F.Dose-AUCt 
relationship for both amoxicillin and clavulanic acid, before a plateau level was reached. It seems 
that in cats a plateau level in the relation AUCt amoxicillin/clavulanic acid was reached much 
earlier, showing the flat slopes and the high y-intercept and AUCt of amoxicillin[20]. 
The 26-mg/kg amoxicillin dose must show capacity-limited absorption like in humans. In the 
ratio AUCt amoxicillin/clavulanic acid high ratios can be obtained with a decrease in the 
denominator. This implies that the high dose of amoxicillin inhibits the absorption of clavulanic 
acid. 
The highest AUCt clavulanic acid values indicate the greatest extent of absorption; all other 
data indicate lesser absorption or a higher rate of elimination by metabolism or hydrolysis. All 
cats were healthy, i.e., presumably with a low and constant amount of bacteria containing β-
lactamase activity. Although the mean plasma concentration-time curves of clavulanic acid in 
both formulations suggest comparable absorption, the variation in the individual absorptions 
amounts a factor of nine, like in humans[21,22,23]. 
Amoxicillin-Clavulanic Acid Dosage Ratio 
The amoxicillin-clavulanic acid dosage ratio is based on clavulanic acid irreversibly binding to β-
lactamases. When 80% of an oral amoxicillin dose is excreted unchanged in the urine, 20% 
remains for enzymatic degradation[24,25,26]. The dosage ratio of 4:1 is understandable; 
however, the total amount of bacteria with β-lactamase activity in each animal or human patient 
is unknown.  
In humans, a dose ratio of 10:1 (50/5 mg/kg) has been used for intravenous infusion (0.5 h), 
which resulted in a AUCt ratio of 10 and an identical plasma clearance[21]. In goats, an 
intravenous dose ratio of 20/5 mg/kg resulted in an AUCt ratio of 4.4 and an identical plasma 
clearance [16]. 
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Principal Parameters for the AUCt 
The variation in AUCt amoxicillin is twofold, while that of clavulanic acid is ninefold. The 
regression lines of the three apparent subgroups show a high y-intercept of approximately 10 
AUCt amoxicillin units (Fig. 4). This suggests that with AUCt clavulanic acid lim X→0 there is 
still substantial AUCt amoxicillin, thus substantial absorption, while there is no clavulanic acid 
present. This can be explained assuming that amoxicillin is first absorbed, or transported by the 
capacity limited transport mechanism into the general circulation, and that thereafter, depending 
on the free transport capacity clavulanic acid will be absorbed[27]. If sequential absorption would 
be the case, then there would be a difference in tmax between amoxicillin and clavulanic acid. This 
is present, though the tmax clavulanic acid is only 50% of that of amoxicillin (tmax = 1.47 ± 0.44 h, 
1.57 ± 0.43 vs. 0.72 ± 0.26 h, 0.81 ± 0.23 h, respectively, in Table 1). Most likely, amoxicillin 
and clavulanic acid start to be absorbed at the same moment, while after a while clavulanic acid 
absorption will be limited or inhibited by amoxicillin, leading to the smaller tmax.  
CONCLUSION 
From this study it is learned that the 25/6.25-mg/kg (80/20-mg) dose gives a ninefold variation in 
the absorption or in the final AUCt value of clavulanic acid. The high dose of amoxicillin may 
interfere with or inhibit the absorption of clavulanic acid. This indicates that even (animal) 
patients with a resulting 1:36 AUCt ratio may or must benefit from the presence of clavulanic 
acid. Clinical efficacy will be reached by an apparent overly high proportion of clavulanic acid in 
fixed-dose combination preparations. 
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